OpGen Inc
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, includ… Read more
OpGen Inc (OPGN) - Net Assets
Latest net assets as of September 2025: $10.16 Million USD
Based on the latest financial reports, OpGen Inc (OPGN) has net assets worth $10.16 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.64 Million) and total liabilities ($2.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.16 Million |
| % of Total Assets | 80.37% |
| Annual Growth Rate | -0.76% |
| 5-Year Change | -82.09% |
| 10-Year Change | 133.01% |
| Growth Volatility | 165.67 |
OpGen Inc - Net Assets Trend (2012–2025)
This chart illustrates how OpGen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OpGen Inc (2012–2025)
The table below shows the annual net assets of OpGen Inc from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.38 Million | 0.00% |
| 2024-12-31 | $7.38 Million | +163.84% |
| 2023-12-31 | $-11.56 Million | -252.61% |
| 2022-12-31 | $7.58 Million | -81.62% |
| 2021-12-31 | $41.22 Million | +94.50% |
| 2020-12-31 | $21.19 Million | +393.58% |
| 2019-12-31 | $4.29 Million | +29.76% |
| 2018-12-31 | $3.31 Million | +136.17% |
| 2017-12-31 | $1.40 Million | -55.77% |
| 2016-12-31 | $3.17 Million | -57.72% |
| 2015-12-31 | $7.49 Million | +192.88% |
| 2014-12-31 | $-8.07 Million | -340.40% |
| 2013-12-31 | $-1.83 Million | -122.47% |
| 2012-12-31 | $8.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OpGen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21790749800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $100.71K | 1.36% |
| Other Components | $300.78 Million | 4075.27% |
| Total Equity | $7.38 Million | 100.00% |
OpGen Inc Competitors by Market Cap
The table below lists competitors of OpGen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lian Hong Art. Co., Ltd.
TWO:6755
|
$12.63 Million |
|
CHINA NEW ENERGY LS-00025
F:9H5
|
$12.63 Million |
|
Lokum Deweloper SA
WAR:LKD
|
$12.64 Million |
|
Healthconn Corp.
TWO:6665
|
$12.64 Million |
|
PTL Enterprises Limited
NSE:PTL
|
$12.63 Million |
|
United Express Inc
PINK:UNXP
|
$12.63 Million |
|
Marfin Investment Group Holdings S.A
AT:MIG
|
$12.63 Million |
|
NBI Bearings Europe S.A.
MC:NBI
|
$12.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OpGen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,380,628 to 7,380,628, a change of 0 (0.0%).
- Net income of 11,992,780 contributed positively to equity growth.
- Other factors decreased equity by 11,992,780.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $11.99 Million | +162.49% |
| Other Changes | $-11.99 Million | -162.49% |
| Total Change | $- | 0.00% |
Book Value vs Market Value Analysis
This analysis compares OpGen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-1710.03 | $4.00 | x |
| 2014-12-31 | $-7530.93 | $4.00 | x |
| 2015-12-31 | $5973.72 | $4.00 | x |
| 2016-12-31 | $12519.69 | $4.00 | x |
| 2017-12-31 | $2475.26 | $4.00 | x |
| 2018-12-31 | $220.26 | $4.00 | x |
| 2019-12-31 | $53.11 | $4.00 | x |
| 2020-12-31 | $268.23 | $4.00 | x |
| 2021-12-31 | $224.78 | $4.00 | x |
| 2022-12-31 | $31.03 | $4.00 | x |
| 2023-12-31 | $-14.68 | $4.00 | x |
| 2024-12-31 | $0.73 | $4.00 | x |
| 2025-12-31 | $1.41 | $4.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OpGen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 162.49%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 230.80%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.34x
- Recent ROE (162.49%) is above the historical average (-227.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -174.30% | -244.90% | 0.55x | 1.30x | $-15.02 Million |
| 2013 | 0.00% | -420.36% | 0.76x | 0.00x | $-9.95 Million |
| 2014 | 0.00% | -137.45% | 1.55x | 0.00x | $-4.86 Million |
| 2015 | -231.64% | -549.46% | 0.23x | 1.84x | $-18.10 Million |
| 2016 | -605.11% | -476.11% | 0.45x | 2.84x | $-19.48 Million |
| 2017 | -1098.71% | -479.38% | 0.49x | 4.73x | $-15.53 Million |
| 2018 | -404.02% | -453.77% | 0.33x | 2.71x | $-13.70 Million |
| 2019 | -289.89% | -355.70% | 0.34x | 2.43x | $-12.88 Million |
| 2020 | -123.69% | -622.00% | 0.08x | 2.35x | $-28.33 Million |
| 2021 | -84.45% | -808.31% | 0.06x | 1.74x | $-38.93 Million |
| 2022 | -492.12% | -1430.11% | 0.10x | 3.41x | $-38.04 Million |
| 2023 | 0.00% | -955.79% | 1.82x | 0.00x | $-31.51 Million |
| 2024 | 162.49% | 230.80% | 0.53x | 1.34x | $11.25 Million |
| 2025 | 162.49% | 230.80% | 0.53x | 1.34x | $11.25 Million |
Industry Comparison
This section compares OpGen Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $498,972,584
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OpGen Inc (OPGN) | $10.16 Million | -174.30% | 0.24x | $12.63 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-2.23 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $187.53 Billion |
| Acarix AB (publ) (ACIXF) | $51.88 Million | -150.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $3.82 Million |
| Adm Tronics Unltd (ADMT) | $644.00K | 0.00% | 0.66x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $732.88K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $916.00 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $8.41 Million |